TY - JOUR
T1 - VRK3 depletion induces cell cycle arrest and metabolic reprogramming of pontine diffuse midline glioma - H3K27 altered cells
AU - Menez, Virginie
AU - Kergrohen, Thomas
AU - Shasha, Tal
AU - Silva-Evangelista, Claudia
AU - Le Dret, Ludivine
AU - Auffret, Lucie
AU - Subecz, Chloé
AU - Lancien, Manon
AU - Ajlil, Yassine
AU - Vilchis, Irma Segoviano
AU - Beccaria, Kévin
AU - Blauwblomme, Thomas
AU - Oberlin, Estelle
AU - Grill, Jacques
AU - Castel, David
AU - Debily, Marie Anne
N1 - Publisher Copyright:
Copyright © 2023 Menez, Kergrohen, Shasha, Silva-Evangelista, Le Dret, Auffret, Subecz, Lancien, Ajlil, Vilchis, Beccaria, Blauwblomme, Oberlin, Grill, Castel and Debily.
PY - 2023/1/1
Y1 - 2023/1/1
N2 - We previously identified VRK3 as a specific vulnerability in DMG-H3K27M cells in a synthetic lethality screen targeting the whole kinome. The aim of the present study was to elucidate the mechanisms by which VRK3 depletion impact DMG-H3K27M cell fitness. Gene expression studies after VRK3 knockdown emphasized the inhibition of genes involved in G1/S transition of the cell cycle resulting in growth arrest in G1. Additionally, a massive modulation of genes involved in chromosome segregation was observed, concomitantly with a reduction in the level of phosphorylation of serine 10 and serine 28 of histone H3 supporting the regulation of chromatin condensation during cell division. This last effect could be partly due to a concomitant decrease of the chromatin kinase VRK1 in DMG following VRK3 knockdown. Furthermore, a metabolic switch specific to VRK3 function was observed towards increased oxidative phosphorylation without change in mitochondria content, that we hypothesized would represent a cell rescue mechanism. This study further explored the vulnerability of DMG-H3K27M cells to VRK3 depletion suggesting potential therapeutic combinations, e.g. with the mitochondrial ClpP protease activator ONC201.
AB - We previously identified VRK3 as a specific vulnerability in DMG-H3K27M cells in a synthetic lethality screen targeting the whole kinome. The aim of the present study was to elucidate the mechanisms by which VRK3 depletion impact DMG-H3K27M cell fitness. Gene expression studies after VRK3 knockdown emphasized the inhibition of genes involved in G1/S transition of the cell cycle resulting in growth arrest in G1. Additionally, a massive modulation of genes involved in chromosome segregation was observed, concomitantly with a reduction in the level of phosphorylation of serine 10 and serine 28 of histone H3 supporting the regulation of chromatin condensation during cell division. This last effect could be partly due to a concomitant decrease of the chromatin kinase VRK1 in DMG following VRK3 knockdown. Furthermore, a metabolic switch specific to VRK3 function was observed towards increased oxidative phosphorylation without change in mitochondria content, that we hypothesized would represent a cell rescue mechanism. This study further explored the vulnerability of DMG-H3K27M cells to VRK3 depletion suggesting potential therapeutic combinations, e.g. with the mitochondrial ClpP protease activator ONC201.
KW - VRK3
KW - cell cycle arrest
KW - diffuse midline glioma H3 K27-altered
KW - oxidative phosphorylation (OXPHOS)
KW - pediatric glioma
UR - http://www.scopus.com/inward/record.url?scp=85174896166&partnerID=8YFLogxK
U2 - 10.3389/fonc.2023.1229312
DO - 10.3389/fonc.2023.1229312
M3 - Article
AN - SCOPUS:85174896166
SN - 2234-943X
VL - 13
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 1229312
ER -